Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Scientists Achieve Successful Target Genome Insertion Correction in Human Hematopoietic Stem Cells

By BiotechDaily International staff writers
Posted on 17 Jun 2014
Italian scientists have accomplished an efficient zinc finger nuclease (ZFN)-mediated, targeted gene insertion that resulted in correction of the genetic defect in stem cells from an individual with X-linked severe combined immunodeficiency (SCID-X1).

Significantly, the study demonstrates that the treatment effectively targets a type of hematopoietic stem cells (HSCs) that are responsible for the long-term repopulation of the bone marrow following a transplant procedure. The data support the clinical translation of this strategy for SCID-X1, and other immunodeficiencies and monogenic diseases.

“The ability to accomplish targeted integration of a therapeutic gene into HSCs represents a major step forward in the quest for more precise and safe gene therapies,” stated Luigi Naldini, MD, PhD, director, San Raffaele Telethon Institute for Gene Therapy (TIGET; Milan, Italy), and a senior author of the study. “We used ZFNs to promote insertion of a corrective DNA sequence into the IL2RG gene in HSCs derived from either cord blood or bone marrow. This strategy enables correction of the inherited functional defect of the gene while at the same time restoring its expression under physiological control. This work should open a path to the development of safer and potentially curative treatments for SCID-X1 and, conceivably, other genetic disorders.”

The study, was conducted at TIGET by a team of scientists led by Dr. Naldini in collaboration with Sangamo scientists, and was published online May 28, 2014, in the journal Nature. Researchers exploited the fact that ZFN-mediated genome editing requires only a transient expression of the ZFNs to effect a permanent change in the genome. They used messenger RNA and electroporation to deliver the ZFNs and a non-integrating vector, an integrase-defective lentiviral vector (IDLV), to provide a corrective therapeutic DNA sequence, a so-called “donor template,” to human stem cells. This delivery approach, in combination with modified culture conditions for the cells, increased the effectiveness of gene transfer and targeted integration, especially in more primitive longer-lasting stem cells, to levels that can be used therapeutically to potentially treat a range of monogenic diseases.

The study, which included assessing the proposed gene correction strategy in vitro in HSCs derived from the bone marrow of a symptomatic four-month-old SCID-X1 patient, demonstrated the functional re-formation of the IL2RG gene in the lymphoid progeny of corrected HSCs in vivo.

“Sangamo’s ZFN gene-editing platform provides precise permanent targeted integration of therapeutic genes in contrast to conventional integrating vector approaches which insert genes randomly,” stated Philip Gregory, D. Phil., Sangamo’s senior vice president, research and chief scientific officer, and a coauthor of the study. “This work demonstrates efficient targeted gene insertion in long-term repopulating HSCs, which support multilineage differentiation in to all cells of the blood. These data support the application of ZFN-mediated gene modification across a range of monogenic diseases.”

Sangamo BioSciences, Inc. (Richmond, CA, USA) is focused on engineering genetic cures for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The company has ongoing phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP therapeutic for the treatment of HIV/AIDS (SB-728-T) and NGF-AAV for Alzheimer’s disease (CERE-110). Sangamo’s other therapeutic programs are focused on monogenic and rare diseases.

Related Links:

San Raffaele Telethon Institute for Gene Therapy
Sangamo BioSciences



WATERS CORPORATION

Channels

Genomics/Proteomics

view channel
Image: Electron micrograph of Hepatitis C virus purified from cell culture. Scale bar is 50 nanometers (Photo courtesy of the Center for the Study of Hepatitis C, the Rockefeller University).

Oxidized LDL Predicts Response to Interferon Treatment of Chronic Hepatitis C and May Be a Treatment Option

Oxidized low-density lipoprotein (oxLDL) in the blood was shown to predict responsiveness to interferon treatment in patients with chronic Hepatitis C virus (HCV) infection and to inhibit spread of the... Read more

Drug Discovery

view channel
Image: Molecular model of the anti-cancer drug 5-fluorouracil (Photo courtesy of Wikimedia Commons).

Novel Microcapsule Approach Reduces Toxic Side Effects of Chemotherapy

Cancer researchers have reduced chemotherapy's toxic side effects by using nanoporous capsules to transport an enzyme to the site of a tumor where it is activated by a selective heating process to convert... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.